Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR.

Ann Oncol. 2019 Aug 19. pii: mdz237. doi: 10.1093/annonc/mdz237. [Epub ahead of print] No abstract available.

PMID:
31430371
2.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
3.

Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.

Mir R, Shaw HM, Nathan PD.

Melanoma Res. 2019 Feb;29(1):102-106. doi: 10.1097/CMR.0000000000000543.

PMID:
30395075
4.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators.

Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.

5.

Metastatic disease from uveal melanoma: treatment options and future prospects.

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD.

Br J Ophthalmol. 2017 Jan;101(1):38-44. doi: 10.1136/bjophthalmol-2016-309034. Epub 2016 Aug 29. Review.

6.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR.

Mol Cancer Ther. 2016 Jan;15(1):172-83. doi: 10.1158/1535-7163.MCT-15-0170. Epub 2015 Oct 20.

7.

Trametinib in metastatic melanoma.

Chopra N, Nathan PD.

Expert Rev Anticancer Ther. 2015;15(7):749-60. doi: 10.1586/14737140.2015.1060127. Review.

PMID:
26107021
9.

Screening Criteria in Breast Cancer Trials: Are They Too Restrictive?

Woolf DK, Miles DW, Nathan PD, Windmill E, Makris A.

Clin Oncol (R Coll Radiol). 2015 Sep;27(9):542. doi: 10.1016/j.clon.2015.04.006. Epub 2015 May 9. No abstract available.

PMID:
25972233
10.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ.

Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20.

11.

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.

King JW, Nathan PD.

Future Oncol. 2014;10(9):1559-70. doi: 10.2217/fon.14.89. Review.

PMID:
25145427
12.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

13.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR.

Ann Oncol. 2014 May;25(5):968-74. doi: 10.1093/annonc/mdu054. Epub 2014 Feb 24.

PMID:
24567366
14.

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.

Vasudev NS, Goh V, Juttla JK, Thompson VL, Larkin JM, Gore M, Nathan PD, Reynolds AR.

Br J Cancer. 2013 Sep 3;109(5):1230-42. doi: 10.1038/bjc.2013.429. Epub 2013 Aug 6.

15.

Vemurafenib in melanoma.

Shaw HM, Nathan PD.

Expert Rev Anticancer Ther. 2013 May;13(5):513-22. doi: 10.1586/era.13.24. Review.

PMID:
23617343
16.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.

J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.

17.

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI.

Lancet Oncol. 2012 Oct;13(10):1055-62. doi: 10.1016/S1470-2045(12)70364-9. Epub 2012 Sep 6.

PMID:
22959186
18.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME.

Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12.

19.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M.

Br J Cancer. 2010 Apr 27;102(9):1355-60. doi: 10.1038/sj.bjc.6605650. Epub 2010 Apr 13.

20.
21.

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis.

Jolly EC, Clatworthy MR, Lawrence C, Nathan PD, Farrington K.

NDT Plus. 2009 Aug;2(4):300-2. doi: 10.1093/ndtplus/sfp048. Epub 2009 Apr 28.

22.

Therapeutic opportunities in noncutaneous melanoma.

Wilkins DK, Nathan PD.

Ther Adv Med Oncol. 2009 Jul;1(1):29-36. doi: 10.1177/1758834009337664.

23.

Epithelial ovarian cancer: a review of current management.

Guppy AE, Nathan PD, Rustin GJ.

Clin Oncol (R Coll Radiol). 2005 Sep;17(6):399-411. Review.

PMID:
16149282
24.

The role of CT scanning in the surveillance of testicular tumours.

Nathan PD, Rustin GR.

Clin Oncol (R Coll Radiol). 2003 May;15(3):121-2. No abstract available.

PMID:
12801048
25.

The biological treatment of renal-cell carcinoma and melanoma.

Nathan PD, Eisen TG.

Lancet Oncol. 2002 Feb;3(2):89-96. Review.

PMID:
11902528
26.

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.

Nathan PD, Gore ME, Eisen TG.

J Clin Oncol. 2002 Mar 1;20(5):1429-30. No abstract available.

PMID:
11870194
28.

Characterization of the cloned BamHI restriction modification system: its nucleotide sequence, properties of the methylase, and expression in heterologous hosts.

Brooks JE, Nathan PD, Landry D, Sznyter LA, Waite-Rees P, Ives CL, Moran LS, Slatko BE, Benner JS.

Nucleic Acids Res. 1991 Feb 25;19(4):841-50.

29.

Characterization of clones of the BamHI methyltransferase gene.

Nathan PD, Brooks JE.

Gene. 1988 Dec 25;74(1):35-6. No abstract available.

PMID:
3248731
30.
31.

An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen.

Nathan PD, Walker L, Hardie D, Richardson P, Khan M, Johnson GD, Ling NR.

Clin Exp Immunol. 1986 Jul;65(1):112-9.

32.

Use of monoclonal antibodies reactive with secretory epithelial cells for the immunocytochemical identification of plasma cells.

Johnson GD, Ling NR, Nathan PD, Hardie DL.

Immunol Lett. 1986 Jun;12(5-6):295-300.

PMID:
3733159
33.

Amino acid precursors of Myxococcus xanthus antibiotic TA.

Fytlovitch S, Nathan PD, Zafriri D, Rosenberg E.

J Antibiot (Tokyo). 1983 Nov;36(11):1525-30.

Supplemental Content

Loading ...
Support Center